Literature DB >> 19525776

Targeted tuberculosis contact investigation saves money without sacrificing health.

Maria Pisu1, Joe Gerald, James E Shamiyeh, William C Bailey, Lynn B Gerald.   

Abstract

BACKGROUND: Health departments require an efficient strategy to investigate individuals exposed to Mycobacterium tuberculosis. The contact priority model (CPM) uses a decision rule to minimize testing of low-risk contacts; however, its impact on costs and disease control is unknown.
METHODS: A cost-effectiveness analysis compared the CPM with the traditional concentric circle approach (CCA) in a simulated population of 1000 healthy, community-dwelling adults with a 10% background rate of latent tuberculosis (TB) infection. The analysis was conducted from the perspective of the Alabama Department of Public Health. Model inputs were derived from the literature and the Alabama Department of Public Health. Lifetime costs (2004 dollars) and outcomes were discounted 3 percent annually. Incremental cost-effectiveness ratios were used to compare the strategies.
RESULTS: Over the lifetime of 1000 simulated contacts, the CPM saved $45,000 but led to 0.5 additional TB cases and 0.24 fewer years of life. The CCA is more effective than the CPM, but it costs $92,934 to prevent one additional TB case and $185,920 to gain one additional life year.
CONCLUSIONS: The CPM reduces costs with minimal loss of disease control and is a viable alternative to the CCA under most conditions.

Entities:  

Mesh:

Year:  2009        PMID: 19525776      PMCID: PMC2763575          DOI: 10.1097/PHH.0b013e31819c3ef2

Source DB:  PubMed          Journal:  J Public Health Manag Pract        ISSN: 1078-4659


  24 in total

Review 1.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

2.  Health-care expenditures for tuberculosis in the United States.

Authors:  R E Brown; B Miller; W R Taylor; C Palmer; L Bosco; R M Nicola; J Zelinger; K Simpson
Journal:  Arch Intern Med       Date:  1995 Aug 7-21

3.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

Authors:  C M Nolan; S V Goldberg; S E Buskin
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

4.  Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.

Authors:  S R Salpeter; G D Sanders; E E Salpeter; D K Owens
Journal:  Ann Intern Med       Date:  1997-12-15       Impact factor: 25.391

5.  Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2005-12-16

6.  American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1986-08

7.  Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis.

Authors:  D N Rose; C B Schechter; M C Fahs; A L Silver
Journal:  Am J Prev Med       Date:  1988 Mar-Apr       Impact factor: 5.043

8.  Isoniazid for the tuberculin reactor: take it or leave it.

Authors:  J Tsevat; W C Taylor; J B Wong; S G Pauker
Journal:  Am Rev Respir Dis       Date:  1988-01

9.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Authors:  D E Kopanoff; D E Snider; G J Caras
Journal:  Am Rev Respir Dis       Date:  1978-06

10.  The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors.

Authors:  D N Rose; C B Schechter; A L Silver
Journal:  JAMA       Date:  1986-11-21       Impact factor: 56.272

View more
  1 in total

1.  Optimizing community screening for tuberculosis: Spatial analysis of localized case finding from door-to-door screening for TB in an urban district of Ho Chi Minh City, Viet Nam.

Authors:  Luan Nguyen Quang Vo; Thanh Nguyen Vu; Hoa Trung Nguyen; Tung Thanh Truong; Canh Minh Khuu; Phuong Quoc Pham; Lan Huu Nguyen; Giang Truong Le; Jacob Creswell
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.